Taysha Gene Therapies (TSHA) Other Working Capital Changes (2020 - 2026)

Taysha Gene Therapies has reported Other Working Capital Changes for 3 years, with the latest figure at -$5.5 million in Q4 2025.

• Quarterly Other Working Capital Changes fell 171.27% year-over-year to -$5.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$9.8 million (down 17.28% YoY) and the FY2025 annual result came in at -$9.8 million, down 17.28% from the prior year.
• Other Working Capital Changes retreated to -$5.5 million in Q4 2025 per TSHA's latest filing, from -$2.0 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $2.1 million in Q4 2025 and troughed at -$3.5 million in Q3 2023.
• A 5-year average of -$339882.4 and a median of -$271000.0 in 2022 frame the typical range for Other Working Capital Changes.
• The sharpest annual moves came in 2024 and 2025: Other Working Capital Changes soared 62.33% in 2024, then slumped 171.27% in 2025.
• Over 3 years, Other Working Capital Changes stood at -$3.6 million in 2023, then soared by 43.9% to -$2.0 million in 2024, then plunged by 171.27% to -$5.5 million in 2025.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$5.5 million, -$2.0 million, and -$2.3 million for Q4 2025, Q2 2025, and Q1 2025 respectively.